No big deals for Gilead, analyst says; Merck has to fight Vioxx investor claims; LA sues AstraZeneca over Toprol XL;

@FiercePharma: Paul Allen Just Got One Step Closer To Mapping The Human Brain. More from Forbes | Follow @FiercePharma

@EricPFierce: Will Sun's Shanghvi use his top dog standing to influence other Indian drugmakers to step up their game? Check out the feature from FierceBiotech | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Contrave controversy puts Orexigen, Takeda in unwelcome spotlight. Article | Follow @CarlyHFierce

> Don't expect any mega-size buyouts from Gilead Sciences ($GILD), analysts say, expecting the California-based biotech to stick to pipeline-building deals. Report

> Merck & Co. ($MRK) has to fight investor claims that it concealed the risks of its now-withdrawn painkiller Vioxx. Report

> Louisiana Attorney General Buddy Caldwell sued AstraZeneca ($AZN), claiming the company used "baseless patent infringement lawsuits" and other techniques to keep its monopoly on the cardiovascular drug Toprol XL. Report

> Japanese drugmaker Daiichi Sankyo says it plans to buy back up to 3.98% of its own shares. Report

> Slovenia-based Krka posted a 30% hike in first-quarter profits, thanks to the strengthening Russian rouble; sales in Russia fell in euro terms. Report

> FedEx ($FDX) wants credit for helping law enforcement crack down on illegal online pharmacies. Report

> A bill allowing biosimilar substitution, with doctor notification, advanced in the New Jersey Assembly. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: Glaucoma micro stent player Glaukos files to raise up to $86M in an IPO. Article | Follow @FierceMedDev

@VarunSaxena2: Philips quality improvement plan hit by recall at its troubled Cleveland facility. Report | Follow @VarunSaxena2

@EmilyWFierce: Which global markets should drugmakers target? China, yes--but old European standbys, too. More from FiercePharma | Follow @EmilyWFierce

> Medtronic's vein closure device recalled in Europe, Asia right around time of its U.S. launch. More

> FDA clears BD insulin infusion pump designed with diabetes patient advocacy groups. Article

Biotech News

@FierceBiotech: Special report: The 25 most influential people in biopharma in 2015. Feature | Follow @FierceBiotech

@JohnCFierce: Talked to two of the founders at Denali, which just drew a $217M round for neurodegeneration R&D. More | Follow @JohnCFierce

> Eli Lilly to work with Sanford-Burnham on autoimmune diseases. Item

> MPM rounds up $400M for biotech VC with Novartis and Astellas on board. Story

> Sage steps up to a pivotal PhIII as brain seizure drug aces trial challenge. Article

Pharma Manufacturing News

> Troubled Wockhardt recalls blood pressure med in U.S. Story

> Romark recalls pediatric diarrhea treatment Alina. News

> Sun and Ranbaxy marriage puts Sun founder Shanghvi in position to influence industry. Item

> Danaher, drawn by Pall's biopharma biz, will pay $13.8B for filtration specialist. Article

> Perrigo buys Patheon's softgel operations in Mexico. Report

Pharma Asia News

> Japan's MHLW sets Sovaldi price, hep C competition heats up. More

> Ranbaxy faces U.S. racketeering suit for blocking launch of Roche, Novartis generics. Story

> India's Lupin buys Brazil's Medquimica as part of M&A growth plan. Report

> Australia budget promises more digging on reimbursement, fees. Item

> Japan readies to sign new IP law it sees as win-win. Article

Vaccines News

> NewLink continues cancer vaccine Ph III trial with interim data under wraps. Story

> BiondVax rounds up $9.5M in IPO. Item

> Bavarian Nordic smallpox vaccine scores two late-stage trial wins. Article

> NIH-backed West Nile candidate enters PhI trials at Duke. Story

> Nima Farzan takes over as PaxVax CEO. Report

CRO News

> QPS cuts the ribbon on a new lab for early-stage R&D. News

> Theorem expands in Europe with new supplies facility. More

> Evotec brightens its outlook after $286M Sanofi deal. Report

> Patheon sells off its Mexican division for $34M. Item

> WuXi weighs going private with a deal on the table. Article

And Finally... CVS ($CVS) agreed to pay $22 million to resolve a federal investigation into painkiller sales in Florida. Report